The Cytokinetics second generation troponin activator, reldesemtiv , is intended to treat muscle weakness by directly activating skeletal muscle. A high concentration of free drug is expected to be needed due to the large amount of fast skeletal muscle troponin in the body, making safety and selectivity critical. Reldesemtiv demonstrated [...]